This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

6 Stocks at New 52-Week Highs


Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Inhibitex (INHX) is focused on the development of differentiated anti-infective products to prevent or treat serious infections. This stock is trading up 18% to $10.53 in recent trading, after it hit a 52-week high of $11.98 earlier today.

Today's Range: $11.10-$11.98

52-week Range: $2.00-$11.98

Volume: 7,000,000

Three-Month Average Volume: 1,419,000

Inhibitex has a market cap of $896.45 million and an enterprise value of $646.86 million. Its estimated growth rate for this year is 5.4%, and for next year it's pegged at -5.7%. The current short interest as a percentage of the float for Inhibitex is 3.4%.

This stock is soaring higher today as traders jamp into any stock with exposure to hepatitis C treatments after Gilead Sciences struck a deal to buy Pharmasset for $11 billion. Inhibitex is currently developing hepatitis C medicines.

From a technical standpoint, this stock is gapping up and breaking out above some past overhead resistance at $10.60 today on high volume. If this stock can manage to close above $10.60 and near its daily high of $11.98, then traders should look for continued upside.

That said, if INHX closes below $10.60, then I would expect to see the gap higher today get filled in the near future back toward $8.50.

Inhibitex shows up on a recent list of 13 Biotech Stocks Bought and Sold by Hedge Funds.

2 of 6

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,172.68 -107.06 -0.62%
S&P 500 1,994.29 -16.11 -0.80%
NASDAQ 4,527.6890 -52.10 -1.14%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs